Sacubitril/Valsartan Off-Label Uses for Heart Failure

•Sacubitril/valsartan can be used in inpatients who are hemodynamically stable after acute decompensated heart failure.•There is no compelling indication to use sacubitril/valsartan rather than angiotensin receptor-neprilysin inhibitors in patients with acute coronary syndrome with left ventricular...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of cardiac failure 2022-07, Vol.28 (7), p.1185-1201
Hauptverfasser: Kido, Kazuhiko, Colvin, Bailey M., Szymanski, Thomas W., Guglin, Maya
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1201
container_issue 7
container_start_page 1185
container_title Journal of cardiac failure
container_volume 28
creator Kido, Kazuhiko
Colvin, Bailey M.
Szymanski, Thomas W.
Guglin, Maya
description •Sacubitril/valsartan can be used in inpatients who are hemodynamically stable after acute decompensated heart failure.•There is no compelling indication to use sacubitril/valsartan rather than angiotensin receptor-neprilysin inhibitors in patients with acute coronary syndrome with left ventricular ejection fraction ≤ 40%.•Sacubitril/valsartan may be indicated in patients with left ventricular assist devices or chemotherapy-induced cardiomyopathy or patients with heart failure who are on dialysis. Sacubitril/valsartan is an angiotensin receptor/neprilysin inhibitor that the Food and Drug Administration has indicated to reduce the risk of cardiovascular hospitalization and death in patients with left ventricular ejection fraction below normal and with no specified ejection-fraction cut-off. However, clinically significant patient groups were excluded or minimally represented in sacubitril/valsartan's pivotal clinical trials. Clinicians often encounter scenarios in which a sacubitril/valsartan off-label use may be beneficial, but limited resources are available to evaluate the efficacy and safety in these patients. This state-of-the-art review describes contemporary literature for sacubitril/valsartan Food and Drug Administration off-label indications to help clinicians assess its appropriateness in these selected, clinically important groups of patients: those with acute decompensated heart failure, acute coronary syndrome, peripartum cardiomyopathy, chemotherapy-induced cardiomyopathy, adult congenital heart disease, cardiomyopathy in dialysis patients, right ventricular failure, or durable left ventricular assist device.
doi_str_mv 10.1016/j.cardfail.2022.03.348
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2649593672</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1071916422004572</els_id><sourcerecordid>2649593672</sourcerecordid><originalsourceid>FETCH-LOGICAL-c315t-a83181c86d0189fa11ae734af4315af5e758aae2bd4aa34394c5aed28f7e11fd3</originalsourceid><addsrcrecordid>eNqFkE1PwzAMhiMEYjD4C1OPXFriJmnTGwjxJU3aAcY18lJHytStI2mR-PdkGuPKyZb82K_8MDYDXgCH6nZdWAytQ98VJS_LgotCSH3CLkCJMtcS5GnqeQ15A5WcsMsY15xzLXl9ziZCSa6EhAum3tCOKz8E391-YBcxDLjNFs7lc1xRly0jxcz1IXuhNMqeUuAY6IqduQTT9W-dsuXT4_vDSz5fPL8-3M9zK0ANOWoBGqyuWg66cQiAVAuJTqYxOkW10ohUrlqJKKRopFVIbaldTQCuFVN2c7i7C_3nSHEwGx8tdR1uqR-jKSvZqEZUdZnQ6oDa0McYyJld8BsM3wa42Ssza3NUZvbKDBcmKUuLs9-McbWh9m_t6CgBdweA0qdfnoKJ1tPWUusD2cG0vf8v4wfm1H8i</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2649593672</pqid></control><display><type>article</type><title>Sacubitril/Valsartan Off-Label Uses for Heart Failure</title><source>Access via ScienceDirect (Elsevier)</source><creator>Kido, Kazuhiko ; Colvin, Bailey M. ; Szymanski, Thomas W. ; Guglin, Maya</creator><creatorcontrib>Kido, Kazuhiko ; Colvin, Bailey M. ; Szymanski, Thomas W. ; Guglin, Maya</creatorcontrib><description>•Sacubitril/valsartan can be used in inpatients who are hemodynamically stable after acute decompensated heart failure.•There is no compelling indication to use sacubitril/valsartan rather than angiotensin receptor-neprilysin inhibitors in patients with acute coronary syndrome with left ventricular ejection fraction ≤ 40%.•Sacubitril/valsartan may be indicated in patients with left ventricular assist devices or chemotherapy-induced cardiomyopathy or patients with heart failure who are on dialysis. Sacubitril/valsartan is an angiotensin receptor/neprilysin inhibitor that the Food and Drug Administration has indicated to reduce the risk of cardiovascular hospitalization and death in patients with left ventricular ejection fraction below normal and with no specified ejection-fraction cut-off. However, clinically significant patient groups were excluded or minimally represented in sacubitril/valsartan's pivotal clinical trials. Clinicians often encounter scenarios in which a sacubitril/valsartan off-label use may be beneficial, but limited resources are available to evaluate the efficacy and safety in these patients. This state-of-the-art review describes contemporary literature for sacubitril/valsartan Food and Drug Administration off-label indications to help clinicians assess its appropriateness in these selected, clinically important groups of patients: those with acute decompensated heart failure, acute coronary syndrome, peripartum cardiomyopathy, chemotherapy-induced cardiomyopathy, adult congenital heart disease, cardiomyopathy in dialysis patients, right ventricular failure, or durable left ventricular assist device.</description><identifier>ISSN: 1071-9164</identifier><identifier>EISSN: 1532-8414</identifier><identifier>DOI: 10.1016/j.cardfail.2022.03.348</identifier><identifier>PMID: 35405341</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>heart failure ; off-label ; Sacubitril ; valsartan</subject><ispartof>Journal of cardiac failure, 2022-07, Vol.28 (7), p.1185-1201</ispartof><rights>2022 Elsevier Inc.</rights><rights>Copyright © 2022 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c315t-a83181c86d0189fa11ae734af4315af5e758aae2bd4aa34394c5aed28f7e11fd3</cites><orcidid>0000-0002-3393-8025</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.cardfail.2022.03.348$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35405341$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kido, Kazuhiko</creatorcontrib><creatorcontrib>Colvin, Bailey M.</creatorcontrib><creatorcontrib>Szymanski, Thomas W.</creatorcontrib><creatorcontrib>Guglin, Maya</creatorcontrib><title>Sacubitril/Valsartan Off-Label Uses for Heart Failure</title><title>Journal of cardiac failure</title><addtitle>J Card Fail</addtitle><description>•Sacubitril/valsartan can be used in inpatients who are hemodynamically stable after acute decompensated heart failure.•There is no compelling indication to use sacubitril/valsartan rather than angiotensin receptor-neprilysin inhibitors in patients with acute coronary syndrome with left ventricular ejection fraction ≤ 40%.•Sacubitril/valsartan may be indicated in patients with left ventricular assist devices or chemotherapy-induced cardiomyopathy or patients with heart failure who are on dialysis. Sacubitril/valsartan is an angiotensin receptor/neprilysin inhibitor that the Food and Drug Administration has indicated to reduce the risk of cardiovascular hospitalization and death in patients with left ventricular ejection fraction below normal and with no specified ejection-fraction cut-off. However, clinically significant patient groups were excluded or minimally represented in sacubitril/valsartan's pivotal clinical trials. Clinicians often encounter scenarios in which a sacubitril/valsartan off-label use may be beneficial, but limited resources are available to evaluate the efficacy and safety in these patients. This state-of-the-art review describes contemporary literature for sacubitril/valsartan Food and Drug Administration off-label indications to help clinicians assess its appropriateness in these selected, clinically important groups of patients: those with acute decompensated heart failure, acute coronary syndrome, peripartum cardiomyopathy, chemotherapy-induced cardiomyopathy, adult congenital heart disease, cardiomyopathy in dialysis patients, right ventricular failure, or durable left ventricular assist device.</description><subject>heart failure</subject><subject>off-label</subject><subject>Sacubitril</subject><subject>valsartan</subject><issn>1071-9164</issn><issn>1532-8414</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNqFkE1PwzAMhiMEYjD4C1OPXFriJmnTGwjxJU3aAcY18lJHytStI2mR-PdkGuPKyZb82K_8MDYDXgCH6nZdWAytQ98VJS_LgotCSH3CLkCJMtcS5GnqeQ15A5WcsMsY15xzLXl9ziZCSa6EhAum3tCOKz8E391-YBcxDLjNFs7lc1xRly0jxcz1IXuhNMqeUuAY6IqduQTT9W-dsuXT4_vDSz5fPL8-3M9zK0ANOWoBGqyuWg66cQiAVAuJTqYxOkW10ohUrlqJKKRopFVIbaldTQCuFVN2c7i7C_3nSHEwGx8tdR1uqR-jKSvZqEZUdZnQ6oDa0McYyJld8BsM3wa42Ssza3NUZvbKDBcmKUuLs9-McbWh9m_t6CgBdweA0qdfnoKJ1tPWUusD2cG0vf8v4wfm1H8i</recordid><startdate>20220701</startdate><enddate>20220701</enddate><creator>Kido, Kazuhiko</creator><creator>Colvin, Bailey M.</creator><creator>Szymanski, Thomas W.</creator><creator>Guglin, Maya</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3393-8025</orcidid></search><sort><creationdate>20220701</creationdate><title>Sacubitril/Valsartan Off-Label Uses for Heart Failure</title><author>Kido, Kazuhiko ; Colvin, Bailey M. ; Szymanski, Thomas W. ; Guglin, Maya</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c315t-a83181c86d0189fa11ae734af4315af5e758aae2bd4aa34394c5aed28f7e11fd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>heart failure</topic><topic>off-label</topic><topic>Sacubitril</topic><topic>valsartan</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kido, Kazuhiko</creatorcontrib><creatorcontrib>Colvin, Bailey M.</creatorcontrib><creatorcontrib>Szymanski, Thomas W.</creatorcontrib><creatorcontrib>Guglin, Maya</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cardiac failure</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kido, Kazuhiko</au><au>Colvin, Bailey M.</au><au>Szymanski, Thomas W.</au><au>Guglin, Maya</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sacubitril/Valsartan Off-Label Uses for Heart Failure</atitle><jtitle>Journal of cardiac failure</jtitle><addtitle>J Card Fail</addtitle><date>2022-07-01</date><risdate>2022</risdate><volume>28</volume><issue>7</issue><spage>1185</spage><epage>1201</epage><pages>1185-1201</pages><issn>1071-9164</issn><eissn>1532-8414</eissn><abstract>•Sacubitril/valsartan can be used in inpatients who are hemodynamically stable after acute decompensated heart failure.•There is no compelling indication to use sacubitril/valsartan rather than angiotensin receptor-neprilysin inhibitors in patients with acute coronary syndrome with left ventricular ejection fraction ≤ 40%.•Sacubitril/valsartan may be indicated in patients with left ventricular assist devices or chemotherapy-induced cardiomyopathy or patients with heart failure who are on dialysis. Sacubitril/valsartan is an angiotensin receptor/neprilysin inhibitor that the Food and Drug Administration has indicated to reduce the risk of cardiovascular hospitalization and death in patients with left ventricular ejection fraction below normal and with no specified ejection-fraction cut-off. However, clinically significant patient groups were excluded or minimally represented in sacubitril/valsartan's pivotal clinical trials. Clinicians often encounter scenarios in which a sacubitril/valsartan off-label use may be beneficial, but limited resources are available to evaluate the efficacy and safety in these patients. This state-of-the-art review describes contemporary literature for sacubitril/valsartan Food and Drug Administration off-label indications to help clinicians assess its appropriateness in these selected, clinically important groups of patients: those with acute decompensated heart failure, acute coronary syndrome, peripartum cardiomyopathy, chemotherapy-induced cardiomyopathy, adult congenital heart disease, cardiomyopathy in dialysis patients, right ventricular failure, or durable left ventricular assist device.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>35405341</pmid><doi>10.1016/j.cardfail.2022.03.348</doi><tpages>17</tpages><orcidid>https://orcid.org/0000-0002-3393-8025</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1071-9164
ispartof Journal of cardiac failure, 2022-07, Vol.28 (7), p.1185-1201
issn 1071-9164
1532-8414
language eng
recordid cdi_proquest_miscellaneous_2649593672
source Access via ScienceDirect (Elsevier)
subjects heart failure
off-label
Sacubitril
valsartan
title Sacubitril/Valsartan Off-Label Uses for Heart Failure
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T17%3A19%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sacubitril/Valsartan%20Off-Label%20Uses%20for%20Heart%20Failure&rft.jtitle=Journal%20of%20cardiac%20failure&rft.au=Kido,%20Kazuhiko&rft.date=2022-07-01&rft.volume=28&rft.issue=7&rft.spage=1185&rft.epage=1201&rft.pages=1185-1201&rft.issn=1071-9164&rft.eissn=1532-8414&rft_id=info:doi/10.1016/j.cardfail.2022.03.348&rft_dat=%3Cproquest_cross%3E2649593672%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2649593672&rft_id=info:pmid/35405341&rft_els_id=S1071916422004572&rfr_iscdi=true